Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus  

作　　者：Tatsuo Kanda Shingo Nakamoto Shuang Wu Masato Nakamura Xia Jiang Yuki Haga Reina Sasaki Osamu Yokosuka 

机构地区：[1]Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Inohana, Chuo-ku, Chiba, Japan

出　　处：《Journal of Clinical and Translational Hepatology》2015年第3期205-210,共6页临床与转化肝病杂志（英文版）

摘　　要：Hepatitis A virus (HAV) infection is a major cause of acute hepatitis and occasionally leads to acute liver failure in both developing and developed countries.Although effective vaccines for HAV are available,the development of new antivirals against HAV may be important for the control of HAV infection in developed countries where no universal vaccination program against HAV exists,such as Japan.There are two forms of antiviral agents against HAV:direct-acting antivirals (DAAs) and host-targeting agents (HTAs).Studies using small interfering ribonucleic acid (siRNA) have suggested that the HAV internal ribosomal entry site (IRES) is an attractive target for the control of HAV replication and infection.Among the HTAs,amantadine and interferon-lambda 1 (IL-29) inhibit HAV IRES-mediated translation and HAV replication.Janus kinase (JAK) inhibitors inhibit La protein expression,HAV IRES activity,and HAV replication.Based on this review,both DAAs and HTAs may be needed to control effectively HAV infection,and their use should continue to be explored.Hepatitis A virus (HAV) infection is a major cause of acute hepatitis and occasionally leads to acute liver failure in both developing and developed countries.Although effective vaccines for HAV are available,the development of new antivirals against HAV may be important for the control of HAV infection in developed countries where no universal vaccination program against HAV exists,such as Japan.There are two forms of antiviral agents against HAV:direct-acting antivirals (DAAs) and host-targeting agents (HTAs).Studies using small interfering ribonucleic acid (siRNA) have suggested that the HAV internal ribosomal entry site (IRES) is an attractive target for the control of HAV replication and infection.Among the HTAs,amantadine and interferon-lambda 1 (IL-29) inhibit HAV IRES-mediated translation and HAV replication.Janus kinase (JAK) inhibitors inhibit La protein expression,HAV IRES activity,and HAV replication.Based on this review,both DAAs and HTAs may be needed to control effectively HAV infection,and their use should continue to be explored.

关 键 词：AMANTADINE DAA HAV HTA La protein Drug overview 

分 类 号：R51[医药卫生—内科学]